凝血酶激活的纤溶抑制物与妊娠
摘要
凝血酶激活的纤溶抑制物(TAFI)是近年来发现存在于血浆中的一种蛋白酶原,在被凝血酶、血栓调节蛋白、纤溶酶等激活后可以下调纤溶活性,对纤维蛋白溶解有抑制作用。TAFI的发现和研究将为临床防治血栓性疾病如由于血栓倾向造成的不良妊娠早期预防性治疗提供新的思路,现对TAFI的理化性质、生理功能及与妊娠的相关性研究做如下综述。
参考文献19
-
1Henry M,Aubert H ,Morange PE, et al. Identification of polymorphisms in the promoter and the 3'region of the TAFI gene : evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood .2001.97(7) :2053-2058.
-
2Brouwers GT, vos HL ,Leebeek FWG, et al. A novel, possiblyfunctional ,single nucleotide polymorphism in the coding region of the thrombin activatable fibrinolysis inhibitor(TAFI) gene is alsoassociated with TAFI levels.Blood ,2001,98(6) : 1992-1993.
-
3Brouwers GJ, Leebeek FW, Tanck MW,et al.Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome inpatients with unstable angina pectoris.Thromb Haemost,2003,90(1):92-100.
-
4Schneider M, Boffa M, Stewart R,et al. Two naturally occurring variants of TAFI ( Thr-325 and Ile-325) differ substantially with respect tothermal stability and antifibrinolytic activity of the enzyme.J Biol Chem ,2002, 277(9):1021-1030.
-
5Peetz D, Victor A, Adams P, et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb Haemost, 2004,92(2):344-351.
-
6Neili EK, Stewart RJ, Schneider MM, et al. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.Anal Biochem,2004,330(2):332-341.
-
7Chetaille P, Alessi MC, Kouassi D, et al. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost ,2000,83(6) :902-905.
-
8Barbosa Pereira PJ,Segura-Martin S ,Oliva B, et al. Hunmn pro-carboxypeptidase B: three-dimensional structure and implicationsfor thrombin activatable fibrinolysis inhibitor. J Mol Bio1,2002,321(3) :537-547.
-
9Mosnier LO, Meijers JC, Bouma BN. Regulation of Fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrmbomodulin. Thvomb Haemost,2001,85(1):5-11.
-
10Santamaria A, Borrell M, Oliver A, et al. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.Am J Hematol, 2004,76(4):348-352.
-
1刘利妍,刘向群.凝血酶激活的纤溶抑制物与炎症性疾病关系的研究进展[J].国外医学（老年医学分册）,2006,27(5):200-203. 被引量：2
-
2李晓娜,马德庆,李子安.肾病综合征患者血浆凝血酶激活的纤溶抑制物的检测及评价[J].青海医药杂志,2012,42(4):59-60. 被引量：2
-
3郭为民,王鸿利.凝血酶激活的纤溶抑制物[J].中华血液学杂志,2001,22(3):161-163.
-
4叶新明.凝血酶激活的纤溶抑制物与血栓性疾病关系的研究进展[J].实用临床医学（江西）,2010,11(5):123-125. 被引量：2
-
5王洁,王进,朱殿春.舒适护理在分娩产妇中的应用[J].中文科技期刊数据库(文摘版)医药卫生,2016(4):00047-00047.
-
6高光仙.舒适护理在分娩期产妇50例中的应用[J].中国民族民间医药,2016,25(1):120-121. 被引量：3
-
7王波.妊娠期高血压患者的综合护理干预效果分析[J].中国医药指南,2016,14(36):270-271.
-
8张连云.慢性肾小球肾炎患者血清凝血酶激活的纤溶抑制物和肿瘤坏死因子的水平变化及临床意义[J].中国现代医学杂志,2010,20(15):2359-2361. 被引量：18
-
9崔桂萍,杨萍,胡静仪,王颖,姚智.脑卒中患者血浆凝血酶激活的纤溶抑制物的临床研究[J].检验医学,2009,24(1):1-4. 被引量：4
-
10李晓燕.综合护理干预预防糖尿病孕产妇不良妊娠的效果分析[J].实用临床医药杂志,2017,21(6):151-155. 被引量：34
